Share this article
TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/
Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo
Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200 mg dose to EUA
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of detailed results from the Phase 3 pivotal trial showing REGEN–COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19. These data were presented at the 2021 American Thoracic Society International Conference (ATS 2021) in the
Regeneron Presents Detailed Results From Phase 3 Pivotal Trial For REGEN-COV
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced Monday the presentation of detailed results from the Phase 3 pivotal trial showing REGEN-COV (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19.
These data were presented at the 2021 American Thoracic Society International Conference (ATS 2021) in the Breaking News: Clinical Trial Results in Pulmonary Medicine Scientific Symposium, which features late-breaking information on leading clinical trials in pulmonary and critical care medicine.
The company noted that despite increasing vaccination rates, many continue to be diagnosed with COVID-19 who could benefit from REGEN-COV due to underlying conditions like asthma or COPD that put them at higher risk for severe disease.
Regeneron (REGN), Sanofi (SNY) pivotal data at ATS 2021 show Dupixent significantly reduced asthma attacks and improved lung function in children streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.